CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

用于预测转移性透明细胞肾细胞癌患者抗 PD-1 治疗结局的组合生物标志物

英文原题：Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma.

查看英文原题

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma.

PubMed 2023/02/21（内容时间） Cell Rep Med Q1 · IF 14（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

肾细胞癌地区：美国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

中文摘要

对于转移性透明细胞肾细胞癌患者，免疫治疗领域发展迅速，因此亟需疗效生物标志物以指导治疗策略。苏木精-伊红（H&E）染色切片成本低且病理实验室普遍可得，包括资源有限地区的实验室。本研究在三个接受免疫检查点阻断治疗的独立患者队列中发现，对治疗前肿瘤样本进行光学显微镜H&E评分所得的肿瘤浸润免疫细胞（TIL⁺）水平较高，与总生存期（OS）改善相关。单独的坏死评分与OS无关；然而，坏死会改变TIL⁺的预测效应，这一发现对组织生物标志物的转化开发具有广泛意义。将PBRM1突变状态与H&E评分结合，可进一步优化结局预测（OS，p=0.007；客观缓解，p=0.04）。这些发现凸显了H&E评估在未来前瞻性随机试验和新兴多组学分类器的生物标志物开发中的价值。

展开英文摘要原文

With a rapidly developing immunotherapeutic landscape for patients with metastatic clear cell renal cell carcinoma, biomarkers of efficacy are highly desirable to guide treatment strategy. Hematoxylin and eosin (H&E)-stained slides are inexpensive and widely available in pathology laboratories, including in resource-poor settings.

Here, H&E scoring of tumor-infiltrating immune cells (TIL plus ) in pre-treatment tumor specimens using light microscopy is associated with improved overall survival (OS) in three independent cohorts of patients receiving immune checkpoint blockade.

Necrosis score alone does not associate with OS; however, necrosis modifies the predictive effect of TIL plus , a finding that has broad translational relevance for tissue-based biomarker development. PBRM1 mutational status is combined with H&E scores to further refine outcome predictions (OS, p = 0. 007, and objective response, p = 0. 04).

These findings bring H&E assessment to the fore for biomarker development in future prospective, randomized trials, and emerging multi-omics classifiers.

论文信息

作者
Deutsch JS、Lipson EJ、Danilova L、Topalian SL、Jedrych J、Baraban E、Ged Y、Singla N
第一作者单位
Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.United States
通讯作者单位
Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21287, USA. Electronic address: jtaube1@jhmi.edu.United States
文献类型
非美国政府资助研究 · 美国 NIH 资助研究
期刊
Cell reports. Medicine2023 Feb 21
原文标识
PubMed 36812889　·　DOI 10.1016/j.xcrm.2023.100947

在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →